Characterisation of T cells induced by candidate prophylactic vaccines encoding a HIV-1 conserved immunogen in phase I/IIa trial HIVCORE002

Characterisation of T cells induced by candidate prophylactic vaccines encoding a HIV-1 conserved immunogen in phase I/IIa trial HIVCORE002

Bibliographic Details
Main Authors:	Ahmed, T, Borthwick, N, Yang, H, Hancock, G, Yorke, L, Black, A, Ebrahimsa, U, Rose, A, Dorrell, L, Hanke, T
Format:	Conference item
Published:	2011

Similar Items

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
by: Hanke, T, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick, N, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick NJ, et al.
Published: (2012-09-01)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed, T, et al.
Published: (2012)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed T, et al.
Published: (2012-09-01)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes.
by: Borthwick, N, et al.
Published: (2014)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
by: Borthwick, N, et al.
Published: (2013)

Development of prophylactic vaccines against HIV-1.
by: Schiffner, T, et al.
Published: (2013)

Preparation and characterisation of solid dispersions of tanshinone IIA, cryptotanshinone and total tanshinones
by: Xifeng Zhai, et al.
Published: (2017-01-01)

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.
by: Ockenhouse, C, et al.
Published: (1998)

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
by: Peters, B, et al.
Published: (2007)

Prospect of a prophylactic vaccine for HIV.
by: Hanke, T
Published: (2001)

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
by: Ondondo, B, et al.
Published: (2013)

PedVacc001:Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Gambian Infants Born to HIV-1/2-Uninfected Mothers
by: Afolabi, M, et al.
Published: (2011)

Development of prophylactic AIDS vaccines: the current state of affairs.
by: Hanke, T
Published: (2003)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
by: Moyo, N, et al.
Published: (2017)

The bacteriocin from the prophylactic candidate Streptococcus suis 90-1330 is widely distributed across S. suis isolates and appears encoded in an integrative and conjugative element.
by: Yukun Sun, et al.
Published: (2019-01-01)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
by: Borthwick, N, et al.
Published: (2014)

Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine.
by: Bridgeman, A, et al.
Published: (2009)

Prophylactic GSV surgery in elderly candidates for hip or knee arthroplasty
by: Quarto Gennaro, et al.
Published: (2016-01-01)

Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles
by: Melo, Mariane Bandeira, et al.
Published: (2021)

On DNA vaccines and prolonged expression of immunogens.
by: Hanke, T
Published: (2006)

A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9–11 year-old girls and boys – clinical protocol
by: Yi Zeng, et al.
Published: (2019-04-01)

An information theoretic characterisation of auditory encoding.
by: Tobias Overath, et al.
Published: (2007-10-01)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
by: Borthwick, N, et al.
Published: (2014)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
by: Hancock, G, et al.
Published: (2017)

Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa.
by: van Harmelen, J, et al.
Published: (2003)

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans
by: Leonie Mayer, et al.
Published: (2024-01-01)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
by: Howles, S, et al.
Published: (2010)

Immunogenicity of a DNA vaccine candidate for COVID-19
by: Trevor R. F. Smith, et al.
Published: (2020-05-01)

Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate
by: Manette Tanelus, et al.
Published: (2023-11-01)

Safety, immunogenicity and efficacy studies of candidate malaria vaccines FP9 and MVA encoding ME-TRAP in Kenyan children [MIM-PB-224908]
by: Bejon, P, et al.
Published: (2005)

Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
by: Nhan H. Nguyen, et al.
Published: (2021-09-01)

PedVACC 001 and 002: building foundations for infant HIV-1 vaccine trials against breast milk transmission of HIV-1
by: Hanke, T
Published: (2012)

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
by: Richard Stebbings, et al.
Published: (2012-01-01)

Comment on clinical development of candidate HIV vaccines: different problems for different vaccines.
by: McMichael, A, et al.
Published: (2014)

Spatially encoded spectral interferometry for complete characterisation of attosecond XUV pulses
by: Cormier, E, et al.
Published: (2004)

First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody
by: Tingting Ma, et al.
Published: (2022-12-01)

Survival analysis of Stage IIA1 and IIA2 cervical cancer patients
by: Jerry Cheng-Yen Lai, et al.
Published: (2013-03-01)

Characterising independent candidates in Indonesian local politics
by: Dinarto, Dedi, et al.
Published: (2021)